glp 1 stopping Coming off 1s Why Weight Returns After Stopping

For randomised clinical trials, the Jadad scale ( To complement the Jadad score, the Cochrane Risk of Bias Tool (RoB 2) ( For observational studies (cohort and case-control), the NewcastleOttawa Scale (NOS) ( Risk of bias was interpreted as follows: i) Low risk: All criteria met or no more than one rated as unclear

All products discussed are supplied for research purposes only and are not intended for human use

Let's Talk About That Search Query First things first

Healthcare providers may only recommend GLP-1 receptor agonists when BMI is over 30 (i.e., obesity), or if BMI is over 27 and the patient has an associated health condition, such as diabetes, kidney disease, or obstructive sleep apnea

This distinction matters in the GLP-1 market, as regulatory scrutiny, quality controls, and allowable production practices vary significantly between the two models and, as of April 2026, the two tiers face meaningfully different enforcement exposure